FDA Advisory Board In Favor of ALKS 3831 for Schizophrenia
The schizophrenia drug currently has a PDUFA date set for November 15.
Related Articles
Discussing New Updates to GOLD 2025 Report, with Gerard Criner, MD
During his interview, Criner discusses several notable updates to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report regarding COPD care.
Link Identified Between Obesity, Inflammatory Skin Diseases Such as Psoriasis
The investigators of this study noted an association between obesity and conditions such as rosacea, psoriasis, and lichen simplex chronicus.
FDA Accepts Alnylam’s sNDA for Vutrisiran for ATTR-CM
The FDA set the Prescription Drug User Fee Act (PDUFA) date for the investigational RNAi therapeutic as March 23, 2025.
Study Shows Many with Treatment-Resistant Schizophrenia Have a Poor Diet
A study demonstrates many people with treatment-resistant schizophrenia do not comply with nutritional recommendations, which can contribute to increased mortality risk.
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
In this episode, hosts break down a pair of studies from AHA 2024, BPROAD and SUMMIT, as well as a study in JAMA projecting semaglutide…
ONS-5010 for Wet AMD Fails to Meet Noninferiority in NORSE EIGHT Trial
ONS-5010 missed the pre-specified non-inferiority endpoint set with the FDA, but Outlook Therapeutics plans to resubmit the BLA in Q1 of 2025.
A. Sidney Barritt, MD: Real-World Data Suggest Benefit of GLP-1 RAs for MASLD
Barritt reviews real-world data about the use and benefits of GLP-1 RAs in patients with MASLD.
Egg Consumption Through Breast Milk Insufficient for Allergy Prevention in Infants at 12 Months
In this analysis, egg consumption among pregnant mothers was found to be insufficient for the development of oral tolerance to eggs among infants at 1…
Study Identifies Homelessness as a Predictor Against Clozapine Use
A study identified homelessness and minority status as factors that impact clozapine prescription patterns.
Differential Diagnosis of PBC
The panel of experts focus on strategies for distinguishing primary biliary cholangitis (PBC) from other liver diseases with similar clinical presentations, emphasizing key diagnostic markers…